I think the bigger question is whether this company's core business (CRO activities) can be turned around to make money. Is this just a model to collect royalties and milestone payments. This company ran a loss (all the way down to net income) for what the last 7 or 8 quarters? It has also blown a bunch of cash (more than $70M) on buybacks that have done nothing and acquisitions that have not shown any synergy (nice move with an FDA shutdown mandated after plunking down over $20M for an asset. What kind of due diligence was that?). There are more problems that need to be fixed first before i'd say a turnoaround is afoot but i guess one man's floor is another man's ceiling. Best of luck.